Vanguard Group’s Matinas BioPharma MTNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $35K | Hold |
3,982
| – | – | ﹤0.01% | 4276 |
|
|
2025
Q3 | $113K | Hold |
3,982
| – | – | ﹤0.01% | 4212 |
|
|
2025
Q2 | $53.2K | Hold |
3,982
| – | – | ﹤0.01% | 4193 |
|
|
2025
Q1 | $31.1K | Sell |
3,982
-3,118
| -44% | -$27.7K | ﹤0.01% | 4223 |
|
|
2024
Q4 | $54.3K | Sell |
7,100
-5,324
| -43% | -$122K | ﹤0.01% | 4209 |
|
|
2024
Q3 | $660K | Hold |
12,424
| – | – | ﹤0.01% | 3901 |
|
|
2024
Q2 | $1.48M | Hold |
12,424
| – | – | ﹤0.01% | 3663 |
|
|
2024
Q1 | $2.53M | Hold |
12,424
| – | – | ﹤0.01% | 3517 |
|
|
2023
Q4 | $2.01M | Buy |
12,424
+752
| +6% | +$127K | ﹤0.01% | 3600 |
|
|
2023
Q3 | $1.14M | Buy |
11,672
+45
| +0.4% | +$8.29K | ﹤0.01% | 3787 |
|
|
2023
Q2 | $3.14M | Sell |
11,627
-53
| -0.5% | -$18.5K | ﹤0.01% | 3504 |
|
|
2023
Q1 | $4.12M | Buy |
11,680
+205
| +2% | +$77.7K | ﹤0.01% | 3394 |
|
|
2022
Q4 | $4.3M | Buy |
11,475
+235
| +2% | +$117K | ﹤0.01% | 3376 |
|
|
2022
Q3 | $5.36M | Buy |
11,240
+21
| +0.2% | +$12.4K | ﹤0.01% | 3291 |
|
|
2022
Q2 | $6.65M | Buy |
11,219
+706
| +7% | +$404K | ﹤0.01% | 3218 |
|
|
2022
Q1 | $6.34M | Sell |
10,513
-64
| -0.6% | -$35.3K | ﹤0.01% | 3405 |
|
|
2021
Q4 | $8.01M | Buy |
10,577
+69
| +0.7% | +$55.3K | ﹤0.01% | 3346 |
|
|
2021
Q3 | $10.2M | Buy |
10,508
+11
| +0.1% | +$7.12K | ﹤0.01% | 3227 |
|
|
2021
Q2 | $6.1M | Buy |
10,497
+28
| +0.3% | +$18.1K | ﹤0.01% | 3485 |
|
|
2021
Q1 | $8.24M | Buy |
10,469
+204
| +2% | +$205K | ﹤0.01% | 3255 |
|
|
2020
Q4 | $10.5M | Buy |
10,265
+103
| +1% | +$71.5K | ﹤0.01% | 2967 |
|
|
2020
Q3 | $5.84M | Hold |
10,162
| – | – | ﹤0.01% | 3076 |
|
|
2020
Q2 | $5.89M | Buy |
10,162
+63
| +0.6% | +$36.2K | ﹤0.01% | 3030 |
|
|
2020
Q1 | $4.54M | Buy |
10,099
+3,021
| +43% | +$2.74M | ﹤0.01% | 3006 |
|
|
2019
Q4 | $12.1M | Buy |
7,078
+169
| +2% | +$147K | ﹤0.01% | 2770 |
|
|
2019
Q3 | $3.27M | Buy |
6,909
+245
| +4% | +$133K | ﹤0.01% | 3281 |
|
|
2019
Q2 | $4.28M | Buy |
6,664
+1,892
| +40% | +$1.36M | ﹤0.01% | 3221 |
|
|
2019
Q1 | $3.9M | Buy |
4,772
+1,090
| +30% | +$881K | ﹤0.01% | 3222 |
|
|
2018
Q4 | $1.64M | Buy |
3,682
+304
| +9% | +$179K | ﹤0.01% | 3432 |
|
|
2018
Q3 | $2.33M | Sell |
3,378
-21
| -0.6% | -$6.77K | ﹤0.01% | 3475 |
|
|
2018
Q2 | $1.11M | Sell |
3,399
-313
| -8% | -$136K | ﹤0.01% | 3661 |
|
|
2018
Q1 | $2.13M | Buy |
3,712
+113
| +3% | +$89.6K | ﹤0.01% | 3439 |
|
|
2017
Q4 | $3.13M | Buy |
3,599
+85
| +2% | +$82K | ﹤0.01% | 3291 |
|
|
2017
Q3 | $3.48M | Buy |
3,514
+251
| +8% | +$251K | ﹤0.01% | 3241 |
|
|
2017
Q2 | $4.13M | Buy |
+3,263
| New | +$6.57M | ﹤0.01% | 3156 |
|
Other funds holding MTNB
HIW
VF
Vanguard Group's MTNB Position: Q4 2025 in Review
Vanguard Group held its Matinas BioPharma (MTNB) position steady in Q4 2025 at 3,982 shares worth $35K. The position accounts for ﹤0.01% of the portfolio, ranked #4276.
Vanguard Group first reported a position in MTNB in Q2 2017 and has held it in 35 quarters since. The position peaked at $12.1M in Q4 2019. 28 funds tracked by Wall St. Rank hold MTNB as of Q4 2025.
- Vanguard Group held 3,982 shares of Matinas BioPharma worth $35K as of Q4 2025.
- Vanguard Group left its Matinas BioPharma share count unchanged in Q4 2025.
- Matinas BioPharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4276 holding.
- Vanguard Group first reported a position in Matinas BioPharma in Q2 2017 and has held it in 35 quarters since.
- Vanguard Group's Matinas BioPharma position peaked at $12.1M in Q4 2019.
- 28 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.